Literature DB >> 6720731

Severe theophylline toxicity. Role of conservative measures, antiarrhythmic agents, and charcoal hemoperfusion.

A Greenberg, B H Piraino, P D Kroboth, J Weiss.   

Abstract

The presenting symptoms, course, and treatment of 10 patients with severe theophylline toxicity (heart rate above 120, multifocal atrial tachycardia or premature ventricular contractions, hypotension, seizures) are described. Theophylline levels at presentation averaged 66 micrograms/ml (range 30 to 180 micrograms/ml). All patients had marked tachycardia; 80 percent had gastrointestinal symptoms, 50 percent were hypotensive, and 20 percent had seizures. A known history of poor compliance or other risk factors to overdosage was present in 60 percent. Of the five patients in whom drug clearances were determined, two had uniform first-order drug elimination. Three had biphasic elimination with an initial period of delayed elimination due to either zero-order kinetics or continued drug absorption. During the first-order elimination period, mean plasma theophylline clearance was 28.0 +/- 4.3 ml per minute with a half-life of 8.2 hours. In the patients with initially delayed elimination, the mean clearance during the slow phase was 9.6 +/- 3.3 ml per minute with an apparent half-life of 31 hours. One patient was treated with charcoal hemoperfusion but the others received conservative management alone; all recovered without permanent sequelae. Propranolol and verapamil were useful in controlling supraventricular tachycardia. It appears that most patients with severe theophylline toxicity can be managed without hemoperfusion, which should be considered only when drug clearance is reduced, and hypotension, tachycardia, ventricular ectopy, or seizures are refractory to conservative measures.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6720731     DOI: 10.1016/0002-9343(84)90997-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

Review 1.  Adverse reactions and interactions with theophylline.

Authors:  M H Skinner
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

2.  Experience of low-dose aminophylline use to relieve minor adverse effects of dipyridamole in patients undergoing stress myocardial perfusion imaging.

Authors:  Li-Fan Lin; Cheng-Yi Cheng; Cheng-Han Hou; Chih-Hung Ku; Neng-Chuan Tseng; Daniel H Y Shen
Journal:  J Nucl Cardiol       Date:  2014-03-14       Impact factor: 5.952

3.  Theophylline intoxication: toxicokinetic evaluation of hemodialysis.

Authors:  J Bouffard; G Lardet; S Tissot; D Perrot; B Delafosse; J Motin
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

4.  Theophylline poisoning--a review of 64 cases.

Authors:  M J Parr; F C Anaes; A C Day; S L Kletchko; P D Crone; A P Rankin
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

5.  Pentoxifylline alleviates hypertension in metabolic syndrome: effect on low-grade inflammation and angiotensin system.

Authors:  A Azhar; H M El-Bassossy
Journal:  J Endocrinol Invest       Date:  2014-11-21       Impact factor: 4.256

Review 6.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

Review 7.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  Role of extracorporeal drug removal in acute theophylline poisoning. A review.

Authors:  A Heath; K Knudsen
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

9.  Comparison of one versus two bronchodilators in ventilated COPD patients.

Authors:  A Fernandez; J Muñoz; B de la Calle; I Alia; A Ezpeleta; M A de la Cal; A Reyes
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

10.  Severe theophylline poisoning: charcoal haemoperfusion or haemodialysis?

Authors:  R M Higgins; S Hearing; D J Goldsmith; B Keevil; M C Venning; P Ackrill
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.